Higher dose of Crohn's drug shows promise for tough cases
NCT ID NCT00805766
First seen Jan 09, 2026 · Last updated Jun 17, 2026 · Updated 18 times
Summary
This study looked at whether a higher dose (10 mg/kg) of the drug infliximab (TA-650) could help people with Crohn's disease who were not getting enough benefit from the standard dose (5 mg/kg). The 39 participants received the higher dose every 8 weeks. The main goal was to see if their symptoms, measured by a standard Crohn's disease activity index, improved significantly after 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational site
Hokkaido, Japan
-
Investigational site
Kansai, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kyushu, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.